CJC-1295 Dosage Calculator
Calculate exact injection volumes for CJC-1295 using standard reconstitution formulas. Pre-filled for a 5mg vial with 2ml BAC water.
CJC-1295 Dose Reference Table
Pre-calculated for 5mg vial + 2ml BAC water = 2500 mcg/ml concentration.
| Dose (mcg) | Inject Volume (ml) | Syringe Units (100u) |
|---|---|---|
| 100mcg | 0.04 ml | 4 units |
| 200mcg | 0.08 ml | 8 units |
| 300mcg | 0.12 ml | 12 units |
| 400mcg | 0.16 ml | 16 units |
| 500mcg | 0.20 ml | 20 units |
| 1000mcg | 0.40 ml | 40 units |
About CJC-1295
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), belonging to the GHRH peptide class. It was developed by ConjuChem Biotechnologies and is studied for its ability to stimulate growth hormone secretion from the anterior pituitary gland. There are two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF).
CJC-1295 with DAC is notable in research for its exceptionally long half-life of 6–8 days. This extended duration results from the DAC moiety enabling the peptide to bind covalently to serum albumin in the bloodstream, protecting it from enzymatic degradation. This property allows for once-weekly or twice-weekly administration schedules in research protocols, in contrast to native GHRH which has a half-life of only a few minutes.
In preclinical research, CJC-1295 has been studied for its effects on growth hormone and IGF-1 levels, lean body mass, and adipose tissue. Researchers commonly combine it with GHRP-class peptides such as Ipamorelin, as GHRH and GHRP are understood to act synergistically through complementary receptor pathways on the pituitary gland. Standard research vials contain 5mg, typically reconstituted in 2ml bacteriostatic water for a working concentration of 2500 mcg/ml.